Apollo Health Group Launches Genetic Testing Services to Clinicians in Partnership with 1health.io
1health.io Inc. ("1health"), an industry-leading software company that empowers diagnostic laboratories to expand their testing in both the clinical and the direct-to-consumer markets rapidly and securely, partners with Apollo Health Group to bring Apollo's specialized high performing NGS tests, such as hereditary cancer genetic screenings (CGx) and pharmacogenetics screenings (PGx) to the broader clinical market.
Apollo Health Group is streamlining complex genetic testing workflows and eliminating error-prone paper-based processes. Now, using 1health's online portal, physicians located anywhere across the United States can sign up and place orders digitally and securely and process test results quickly and safely.
"With 1health's technology, we are fundamentally changing the way people at risk of cancer and genetic disorders are able to get tested. We have simplified a highly complex process and made it repeatable. Now cancer genetics and pharmacogenetics tests can be ordered in minutes online by any U.S. physician. The results are that people will get faster treatment and lives will be saved," stated Apollo Health Group COO, Blaine Smith. "In addition, we were up and running in 30 days - which is an incredibly fast timeline for a project with this scope," added Smith.
"1health has made an incredibly complex process that includes multi-page patient questionnaires, sophisticated physician diagnosis reports, and laborious insurance documentation easy, fast, and secure," states Mehdi Maghsoodnia, Chief Executive Officer of 1health. "What is even more powerful to understand is that now, through Apollo Health Group, these specialized tests can be ordered by physicians located anywhere across the U.S. It enables Apollo to extend its market reach and help hundreds of thousands of people get access to these genetic tests," added Magsoodnia.
Predictive genetic testing helps a physician understand how a person's genetic composition may affect the body's response to medications and/or how inherited gene mutations might put a person at risk of getting cancer.
The predictive genetic testing market is forecast to grow at 13.9% CAGR and reach USD 3.4 billion by 2027, according to The Market Research Future Report1.
About Apollo Health Group
Apollo Health Group is a laboratory-focused marketing and education platform that owns and operates a CLIA and COLO accredited high complexity molecular laboratory (Apollo Genetics) in Baton Rouge, Louisiana and a CLIA accredited high complexity lab in Draper, Utah (Apollo Diagnostics). The laboratories specialize in marketing and performing NGS tests such as hereditary cancer genetic screenings (CGx) and pharmacogenetics screenings (PGx), a variety of popular PCR tests such as Covid, Women's Health, UTI, Wound Care, Respiratory Pathogen Panels, and a variety of blood tests, including IgE and IgG allergy tests. You can learn about Apollo Health Group at https://www.apollohealthgroup.net/
1health is driving healthcare innovation by revolutionizing the way laboratories service healthcare providers and consumers. By providing a modern, secure, and easy-to-use software platform, 1health enables diagnostic testing results to be accurately delivered in minutes, not days or weeks, thereby reducing costs and expanding growth opportunities for laboratories. The result is stronger, more-trusted relationships between laboratories and their customers, better healthcare outcomes for consumers, and ultimately more lives saved. Learn more at https://1health.io